Roche "Disappointed" By ASCO Focus, Progressing CEA-CD3 Bispecific
Roche CEO Severin Schwan says analysts at ASCO missed a key APHINITY message on Herceptin follow-on Perjeta, and that the Swiss group will swiftly progress its CEA-CD3 bispecific to pivotal studies based on data presented there.
You may also be interested in...
Data from two studies confirm Alecensa's superiority over Pfizer's Xalkori and help Roche close the gap on Novartis' Zykadia.
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.